William J. Meury
CEO & DirectorMr. William J. Meury, also known as Bill, is Chairman of Uniquity Bio, Inc. Mr. Meury serves as Director of Anthos Therapeutics, Inc. since April 2024 and was its Chief Executive Officer since April 2024 until April 2025. He is CEO & Director of Incyte Corporation from June 26, 2025 and was its President from June 26, 2025 to March 25, 2026. He had been President, Chief Executive Officer and Director of Karuna Therapeutics, Inc. until March 18, 2024. He serves as Senior Operating Adviser at Hildred Capital Management, LLC. Previously, he served as a Partner at Hildred Capital Management LLC. He served as Director at Crown Laboratories Inc and served as its Chairman of the Board of Directors until October 2025. He serves on the Board of Directors for Project Natural. He served as the Chief Commercial Officer of Allergan plc until May 8, 2020, having previously served as President, Branded Pharma from March 2015 to May 2016 and Executive Vice President, Commercial, North American Brands from July 2014. He had total P&L responsibility for over 50 products. He served as President, Branded Pharmaceuticals for Actavis. Mr. Meury served as Executive Vice President, Sales and Marketing at Forest prior to its acquisition by Allergan. He joined Forest in 1993 and held multiple roles of increasing responsibility in Marketing, New Products, Business Development and Sales. Before joining Forest, Mr. Meury led three commercial integrations, including the merger between Forest & Actavis, the merger between Actavis & Allergan and the merger between Allergan & Abbvie. Mr. Meury worked in public accounting for Reznick Fedder & Silverman and in financial reporting for MCI Communications. Mr. Meury has experience in biopharmaceuticals and was directly responsible for over 20 new product launches across 10 therapeutic areas during his career. Mr. Meury serves on the Board of Directors of several organizations, including The Jed Foundation, International Council of Ophthalmology Foundation and The Allergan Foundation. Mr. Meury was an Independent Director at Syndax Pharmaceuticals, Inc. since September 25, 2018 until June 24, 2025. He has been involved with over 20 U.S. Food and Drug Administration (FDA) approvals and new product launches. He received a B.A. in Economics from the University of Maryland.
Positions
- Company NameIncyte CorporationStock CodeINCYPositionCEO & DirectorColleagues
- JCJulian Charles BakerIndependent Chairman of the Board
- PJPablo J. CagnoniPresident and Global Head of R&D
- TTThomas TrayPrincipal Financial Officer, VP of Finance & Chief Accounting Officer
- SHSteven H. SteinExecutive VP, Head of Late-stage Development & Chief Medical Officer
- MKMohamed Khairie IssaExecutive Vice President & Head of U.S. Commercial
- JBJean-Jacques BienaimeIndependent Director
- PJPaul J. ClancyIndependent Director
- JAJacqualyn A. FouseIndependent Director
